Antibody Engineering & Therapeutics US is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Junjian Liu, PhD
Vice President, Head of Drug Discovery at Innovent Biologics, Inc.

Profile

Dr. Junjian Liu is Vice President, Head of Drug Discovery at Innovent Biologics, responsible for identifying novel antibody therapeutics and developing early R&D pipeline. Prior to Innovent, he had held various research and managerial positions at WuXi AppTec, AbbVie, Abbott Laboratories, etc. Dr. Liu had built several multi-functional discovery teams covering from early research to preclinical development. He had advanced more than 30 biotherapeutic pipeline projects, and developed several novel antibody format platforms including bispecific antibodies. Several of the molecules he discovered have reached various clinical development stages.

Dr. Liu earned his PhD degree from Peking University, followed by 4 years of postdoctoral training at Northwestern University in Chicago. His academic research was focused on molecular mechanism of carcinogenesis.

Junjian Liu, PhD's Network

Agenda Sessions

  • Durable Blockade of PD-1 Signaling Links Preclinical Efficacy of Sintilimab to its Clinical Benefit

    ,